ADMA Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan ADMA Bio

ADMA Biologics is implementing advanced screening methods to create targeted immunoglobulins. Quarterly earnings per share dynamics allow for an assessment of the business's fundamental stability, where the value 48.80 describes the current level. ADMA Biologics controls the entire production cycle of medications for patients with immunodeficiency. Currently, plants are operating at maximum capacity while simultaneously expanding the network of plasma collection centers.

Quarterly EPS growth measures the dynamics of net profit per share relative to the same period last year. By analyzing the percentage of quarterly EPS change, an investor assesses the business scaling speed and capital management efficiency. The metric is calculated as the ratio of the difference between the current and base values to the base value. A positive trend confirms the commercial viability of ADMA Biologics (ADMA). The effective expansion of plasma centers has provided the company with a stable transition to sustainable profitability.